Hormonal
Thiazolidinediones (specifically Pioglitazone) significantly reduce cardiovascular events (stroke, MI, mortality) in patients with Type 2 Diabetes and macroangiopathies or recent stroke/TIA, independent of glucose lowering.
If you have Type 2 Diabetes and a history of stroke, heart attack, or significant blood vessel disease, ask your doctor about Pioglitazone. It is one of the few diabetes medications proven to significantly reduce the risk of another stroke or heart attack, even in people who do not have diabetes but have insulin resistance. While it can cause side effects like swelling, these are often manageable, and the cardiovascular protection can be life-saving.
In the first of them [PROactive], it was found that pioglitazone significantly reduced overall mortality, as well as the frequency of non-fatal myocardial infarction and stroke. ... In the IRIS study ... the risk of recurrent stroke or myocardial infarction was reduced by 24% compared with the placebo group.
Why this rating
Based on large, randomized, controlled clinical trials (PROactive, IRIS) with clear, statistically significant endpoints.
Source
Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies
В. В. Салухов et al. · Diabetes Mellitus · 2018
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →